NeoGenomics (NEO)
NASDAQ:NEO
Want to see NEO full AI Analyst Report?
NEO Stock Chart & Stats
$8.16
$0.52(2.83%)
At close: 4:00 PM EST
$8.16
$0.52(2.83%)
Day’s Range― - ―
52-Week Range$4.72 - $13.74
Previous CloseN/A
Volume108.49K
Average Volume (3M)1.87M
Market Cap
$1.13B
Enterprise Value$524.51M
Total Cash (Recent Filing)$159.62M
Total Debt (Recent Filing)$472.28M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Apr 28, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding129,812,210
10 Day Avg. Volume2,257,039
30 Day Avg. Volume1,867,457
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.36
Price to Sales (P/S)0.41
P/FCF Ratio-13.83
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue0.72
Enterprise Value/Gross Profit1.71
Enterprise Value/Ebitda-13.58
Forecast
1Y Price Target
$14.75Price Target Upside80.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)0.17
Revenue Forecast (FY)$796.70M
Bulls Say, Bears Say
Bulls Say
Product Portfolio And Revenue MixLaunches of liquid biopsy and MRD tests, combined with trimming a large low-margin contract, should improve the revenue mix and create a portfolio halo that boosts higher-value testing.
ReimbursementMedicare coverage for the blood-based PanTracer test enables reimbursement, which can expand patient access and drive material revenue upside versus current conservative assumptions.
Sales Force Investment And Sequencing GrowthReinvesting operational improvements into the next-generation sequencing sales force supports stronger commercial execution in community oncology and could accelerate test adoption.
Bears Say
Clinical Volume ShortfallCore clinical testing volumes have missed expectations, creating downside risk to revenue if volumes do not recover beyond guidance assumptions.
Margin And Guidance SkepticismDeclining adjusted gross margin and guidance that only meets consensus leave limited room for upside and may sustain investor skepticism until clearer improvements appear.
Product Rollout Execution RiskModest and unevenly timed new product rollouts limit upside potential and expose results to execution risk if launches fail to scale as assumed.
NeoGenomics News
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $4.72 and its highest was $13.74 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.13B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Apr 28, 2026 which is in 10 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Feb 17, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.038 by $0.022.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics dividends here
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is <0.01.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 129,812,210 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.06 in its last earnings report, beating expectations of $0.038. Following the earnings report the stock price went up 0.527%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.75 (80.76% Upside)
$14.75 (80.76% Upside)
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $276.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.9%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.74%
12-Months-Change
Fundamentals
Return on Equity
-12.64%
Trailing 12-Months
Asset Growth
-16.98%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NEO Company Deck
NEO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a constructive operational and commercial story: record FY2025 revenue, robust clinical and NGS growth, new product launches (RADAR ST, PanTracer Pro), strong customer satisfaction (NPS 79), and a confident 2026 financial guide with meaningful adjusted EBITDA growth and a goal to achieve free cash flow positivity. Offsetting these positives are notable headwinds: a significant decline in nonclinical revenue, near-term margin pressure from the Pathline acquisition and launch costs, intentional volume rationalization that temporarily lowered volumes, and timing uncertainty around MolDX reimbursements for key liquid offerings. Management articulated clear strategies to prioritize higher-value testing, expand the salesforce, and deliver LIMS-driven efficiency gains over the coming years.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$14.75
▲(80.76% Upside)
Technical Analysis
Ownership Overview
0.82% Insiders
28.51% Mutual Funds
0.10% Other Institutional Investors
41.06% Public Companies and
Individual Investors